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Tocolysis means drug-induced Inhibition of
premature or excessive uterine activity [38],
Other terms, such äs "sedation of the irritated
myometrium" or "relaxation of the uterus" have
the same meaning; they are, however, not
commonly applied [10, 11, 17, 29].
At the beginning of the research for new sub-
stances with inhibitory effect on the uterus it
was postulated that progesterone or newly-
developed gestagen preparations could inhibit
uterine activity. In vitro äs well äs in vivo ex-
periments showed that progesterone, in con-
centrations present during pregnancy [37, 56],
exerts a synergistic effect on oxytocin and in-
creases uterine activity. High concentrations which
should be applied exclusively for experimental
purposes showed the block inaugurated by
CSAPO [18]. Together with estrogen, progesterone
increases the metabolic activity of the uterus.
Prolonged influence leads to relaxation of the
tissue and increased uterine weight. The collagen
content äs well äs that of nucleic acids, glycogen,
and lipids is raised. The sensitivity to exogenous
Irritation, e. g. uterine distension by the growing
fetus, or to drugs, e. g. oxytocin, increases. Due
to the low solubility in water, the considerable
affinity to serum protein, and a half-life of 15
minutes, even the highest possible concentrations
of progesterone cannot be expected to exert a
sufficient effect on the myometrium [31, 36, 54].
1. Pharmacology of tocolysis
Cinnamedrine was the first ß-adrenergic sub-
stance which, äs reported by SCHULTZ in 1940,
showed a relaxant effect on the smooth muscle;
however, it soon feil into disuse. In 1960 LISH
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et al. [35] published their findings concerning
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ß-adrenergic substance isoxsuprine. First clinical
experiences with isoxsuprine were reported by
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Fig. l. Tocolytics, /?-adrenergic stimulators.
HENDRICKS et al. [27] and BISHOP et al, [13] in
I960. These publications escaped notice in the
German-speaking countries for some time. In
1961 we introduced nylidrin (buphenine, Dik-
tol®), a substance of similar composition which
had akeady been tested on humans in Germany
[17, 38, 55] (Fig. 1), into the treatment of pre-
mature labor.
Doses which were eflfective in the Uterus led
to considerable side effects. In subsequent
years new ^sympathomimetics, kst fenoterol
(Th 1165a), were studied experimentally and
therapeutically [17, 29, 38, 40]. Substances with a
difFetent mode of action, such äs ethyl alcohol
[24], spasmolytic agents of the calcium anta-
gonistic type [23, 40, 41] and, recently, prosta-
gkndin antagonists were also therapeutically
tested [29 43],
To date no drug which acts exlusively or primärily
on the myometrium has been found.
1.1 /?-Adrenergics
Tocolytics äs such are substances with /?-
adrenergic effect on the myometrium. Among all
the substances tested for their effcctivcness in the
Inhibition of labor, the /9-adrenergics show the
best effect with the lowest rate of side effecte.
The effect on the uterus represents only one
component in the total complex of reactions to
adrenergic Irritation. As to the various com-
ponents of this spectrum, the catechokmines and
their derivatives do not show a uniform activity.
Two main groups of effects can be characterized.
One can be easily induced by norepinephrine but
not at all or only slightly by use of isoproterenol
The second group is easily induced by isopro-
terenol, but in most cases not by norepinephrine.
In view of this phenomenon, AHLQUIST [1] postul-
ated two types of adrenergic receptors, a and ß,
and two types of adrenergic drugs, <x-adrenergic
substances (prototype: noradrenalin) and ß~
adrenergic substances (prototype: isoproterenol).
At present the following pattern of action can be
described:
<x-receptors: General excitation of the smooth
muscles, in particukr of the vessels; activation of
hepatic glycogenolysis.
^,-receptors: Positive inotropic, chronotropic
and bathmotropic effects on the heart, rekxation
of the intestinal muscles, Stimulation of lipolysis,
^2-receptors: Likewise lytic effecte on the in-
testinal muscles äs well äs on the smooth muscles
of bronchi, muscukr arterioles and uterus;
activation of the muscular glycogenoiysis.
DAVIS et aL [20] regard the receptors äs isoen-
zymes, According to the pattern of the isoensyme
the effect of the agonists of one substance group
varies between different individuals and different
tissues. At present the /?~receptor is regarded äs
an integrating component of the adenyl
cyclase System, the ^-adrenejrgic effect being
based upon an increase of the intracellular
cAMP leveL It is still aot completely clear in
which way cAMP leads to the rekxation of the
muscle cell and to glycogenolysis, lipolysis and
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protein synthesis in the cell [52]. SCHILD [46]
and RASMUSSEN et al. [45] postulated calcium äs
the main factor for the contracting and relaxant
efFect of sympathomimetics. According to AN-
DERSON et al. [3] the efFect of the ß-receptor
Stimulation is reflected by an increased formation
of cAMP; they assume a Stimulation of the cal-
cium accumulation in the microsomal fraction of
the smooth muscle. The effect on the muscular
tone äs well äs on the cAMP level can be prevented
by£-blockers [4,5,6].
In search of new ß-adrenergic substances with
better tolerance and increased effectiveness,
isoxsuprine (Duvadilan®), nylidrin (Dilatol®)
and other derivatives, such äs Ritodrine®, or-
ciprenaline (Alupent®) and the trial drug Th
1165 a fenoterol (Partusisten®) were used ex-
perimentally and clinically for the Inhibition of
labor [14, 15, 21, 22].
JUNG confirmed that among the tocolytics
tested, fenoterol, Th 1165 a (Partusisten®) shows
the best results with the lowest dosage. Since
1968 we have applied Th 1165 a routinely in the
treatment of premature labor. Using intravenous
drip infusion an immediate tocolytic efFect is
obtained which can easily be controlled. In
selected cases oral administration of Th 1165 a,
too, leads to remarkable Inhibition of labor;
this efFect is obtained within 20 minutes. The
following side-eiFects were observed in 5% of
the patients: Restlessness, muscle tremor, sen-
sations of warmth and heat, flushing of the face,
nausea. An increased pulse rate occurs in mother
and child. When intravenous infusion therapy is
used, these Symptoms are generally found only
at a dosage of more than 2^g/min. For the
evaluation of possible side efFects on the fetus, the
whole spectrum of jS-stimulating changes has to
be considered; i. e. in addition to positive ino-
tropic and chronotropic efFect and vasodilation
in particular metabolic changes such äs glyco-
genolysis and lipolysis must be mentioned [48].
Seripus sequelae of these side-eiFects have not
been reported [42],
«
1.2 Spasmolytics of the papaverine type
Those women treated with Dilatol® in our
hospital since 1963 complained above all of an
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Fig. 2. Spasmolytics.
the jff-adrenergic substance was then combined
with papaverine (Fig. 2). The combination of
these two compounds with their difFerent modes
of action was meant to increase the inhibitory
efFect on the uterus, at the same time reducing
the side-eiFects described above.
In 1914 PAL [44] discovered the relaxant efFect
of papaverine on the smooth muscle. In the
human uterus high doses lead to reduced tone
and decreased frequency of uterine contractions;
Inhibition, however, is only obtained with the
highest possible concentrations. Paperverine has
a negative inotropic efFect on the cardiac muscle
and reduces blood pressure by peripheral vaso-
dilation. These and other side-eiFects elicited by
the high concentrations required, made the cli-
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Fig. 4. Growth of the fetus and prostaglandin release in the
pregnant rat (according to AIKEN) during the last 5 days
before delivery.
nical Implementation of such uterine Inhibition
impossible.
HAAS and HÄRTFELDER [25] developed verapamil
(Isoptin®). Both substances — papaverine äs
well äs verapamil — exert a spasmolytic-mus-
culotropic effect and are regarded äs calcium
antagonists. According to FLECKENSTEIN [23],
electromechanic decoupling leads to Inhibition
of the calcium influx through the depolarized
membrane. From in vivo äs well äs in vitro
experiments it became evident that verapamil
has an inhibitory effect on the Uterus 5 times äs
strong äs papaverine. Even with an acceptable
dosage, however, its effect is inferior to that of
Th 1165 a. Tachycardia following Th 1165 a,
which some patients regarded äs particularly
unpleasant was reduced by simultaneous
administration of verapamil. As is shown in
the studies conducted by WEIDINGER and WIST
•; ^ ^\jr^·^^
Fig. 5. Mechanic and electric activity of the isolated rat
uterus following Stimulation by oxytocin. In high con^
centrations aspirin exerts a direct inhibitory effect on the
uterine activity.
Fig. 6. In the anesthetized rat AspirinD0 inhibits the oxytocin^induced uterine activity (rectal application) Intra-
venous application of prostaglandin 2 leads to renewed uterine activity.
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Pig. 7. Ultrasonic cardiotocography in human. Colfarit® (Aspirin®) l g orally, reduces the uterine activity in the
case of premature labor. Slow onset and efFect lasting several hours has been observed.
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[53] the metabolic side-effects of the /9-sym-
pathomimetics are also decreased by verapamil.
Prostaglandins are involved in the process of
uterine contractility [30]. Anti-inflammatory or
antipyretic agents o£ the Aspirin® or indo-
methacin type (Fig. 3) reduce uterine activity
by Inhibition of prostaglandin formation and
release. VANE [50] demonstrated in animal ex-
periments that prostaglandinsynthesis and release
can be diminished by Aspirin® or indomethacin.
AIKEN found an increase in PGE and PGF like
prostaglandins depending upon the length of
gestation. Rat uteri during parturition produced
20 times more PGF-like substances than uteri at
18—19 days of gestation (Fig. 4). The distension
of the uterine wall by the growing fetus stimulates
the process of prostaglandin formation.
Animal in vitro and in vivo experiments (Figs.
5 to 6) led us to evaluate the effect of long-term
use of Aspirin® in the treatment of threatened
premature labor. In clinical trials we were suc-
cessful in inhibiting premature uterine contrac-
tions with Aspirin® (Fig. 7). In the demonstrated
case at thrity-eight weeks gestation, Aspirin® was
discontinued and spontaneous labor ensued in
4—8 days.
A retrospective survey has been carried out with
103 patients [F. FUCHS, personal communication].
FUCHS had taken high doses of acetylsalicylic acid
for at least the last 6 months of pregnancy and a
comparative study with a suitable population has
been made. Use of Aspirin® was associated with a








Fig, 8, Mechanism of direct action of aspirin on the Uterus.
average length of gestation, in the incidence of
postmaturity, and in the mean duration of
spontaneous labor. . f
The possible acting mechanism of Aspirin® is
shown in Fig. 8.
1.3 Ethyl alcohol
Ethyl alcohol is recommended for the Inhibition
of labor by F. FUCHS [24]. He attributes the
labor-inhibiting effect to blocked oxytocin
release in the neurohypophysis. J. HÜTER
[28] could confirm known labor-inhibiting and
basal tone decreasing properties of ethanol in
the isolated Uterus of rats and mice; ethyl ether
and halothane are also known to possess these
properties. Therefore a peripheral point of
attack cannot be excluded.
With the dosage indicated by F. FUCHS, the blood
alcohol level ranges from 0.10 to 0.16%. In
addition, adequate intake of häfd liquor tenders
oral treatment possible.
1.4 Other substances with inhibitory effect on the
uterus
Progesterone, gestagen, opiates, and benzodiazepine are
only of historical interest, since an inhibitory effect could
not be prpved in clinical tests. Relaxin, atropirie, anti-
histamine, and phenothiazine have also been given without
success for the Inhibition of labor [51].
Among the Opiates there are likewise no substances which,
in a therapeutically acceptable dosage, could sedate the
uterus. These substances may prove detrimental in case of
fetal asphyxia and may lead to hypoventilation, especially
in the premature fetus. Librium® and Valium® are no·
labor-inhibiting agents. Their spasmolytic effect is similar
to that of papaverine. With therapeutical dosage intra-
uterine tocometry did not show any labor-inhibiting effect
in humans [7, 8, 9]. In some cases we use benzodiaSepine
for psychical sedation äs well. If required, analgetics
should also be given.
Theophylline is not being used for tocolysis since we
have the more effective ß-adrenergic substances and
spasmolyti.es. It was recently shown that the effect of
theophylline on the nonpregnant human uterus is that of
relaxation, independent of the phase of the cycle [16, 19].
Due to toxicity or marked side effects, some substances
with tocolytic properties cannot be used äs a routine
measure. Intravenoüs application of magnesium Sulfate
leads to pronounced reduction in contractioii frequency
and amplitude. However, the required blood level con-
centration of 8 to 12 mg% is very close to the toxic thre-
shold dose [51],
Among the Inhalation anesthetics, ether and Chloroform
are known to exert an especially strong effect on the uterus.
J^Perinat. Med. 2 (1974)
Mosler et al., Tocolytic therapy in obstetrics
Chloroform is no longer used because of its narrow
therapeutic ränge and the danger of organic lesions.
Although ether shows an excellent relaxant effect it cannot
be recommended mainly because of the fact t hat it may lead
to vomiting with danger of aspiration and hypoxia of the
fetus [28].
The pharmacological and anesthesiological properties of
halothane are of value for obstetrics: non-inflammability,
rapid onset and subsiding of anesthesia without excitation,
and rapid tocolysis. If general anesthesia is required, e. g.
in case of prolapse of the cord, halothane is the appro-
priate anesthetic. The following disadvantages are to be
mentioned: occasional cardiac irregularities and hypo-
ventilation, insufficient relaxation of the striated muscles,
passage into the fetal circulation with danger of hypoxia
[28]. Halothane sensitizes the heart to catecholamines.
Gases of oxytocin-resistant uterine atony have been re-
ported [51].
2. Clinical conditions required for toco-
lysis
Modern tocolytics are highly effective drugs.
Therefore, tocolysis must be restricted to Hospitals
staffed with obstetricians. Continuous moni-
toring and personal observation during treat-
ment should be possible. The development of
efficient Instruments in the last few years for the
external control of fetal cardiac activity and
uterine activity (phonocardio-tocograph (CTG)
developed by KAMMACHER [26], ultrasonic-
cardio-tocograph (USCTG) developed by MOS-
LER [39]) may be regarded äs advantageous to
large-scale clinical application of drugs for the
Inhibition of labor.
In particular the diagnosis "increased uterine
activity" should be confirmed clinically using
tocography. Biliary äs well äs ureteric and in-
testinal spasms are sometimes mistaken for
premature labor.
In latter years the number of indications for
tocolysis has increased. This supplemented in-
dication list enables a more exact and therefore
more successful determination for tocolysis. A
reduction in the number of premature deliveries
may give rise to hopes of a decrease in perinatal
mortality [8, 10, 11, 18, 29, 43]. Initial reports on
favorable results obtained with tocolysis are
tempered with more pessimistic evaluations [34,
42, 58].
Successful tocolysis requires certain conditions.
2.1 Clinical requirements for tocolysis
a) Coordinate labor with a frequency of l or
more contractions within 10 minutes (toco-
graphy, partogram).
Contractions can often be reduced, by moving
the patient into a lateral position. Patients
Statements regarding pain during contractions
are no reliable criterion for their intensity [28].
b) The parturient patient must be carrying a live
fetus.
c) Estimated fetal weight below 2500 g, or
gestation period up to the 37th week.
d) The cervix is dilated not more than 3 cm.
e) The cervix is effaced no more than 50%
(pelvic score).
2.2 Relative clinical contraindications
a) Obstetric contraindications
Premature rupture of the membranes of the
lower pole,
Temperature above 38°C in case of suspected
intrauterine infection,
Severe hemorrhage in case of placenta praevia,
Premature Separation of the placenta,
Cephalo-pelvic-disproportion, and contracted
pelvis.
b) Medical contraindications with respect to
the fetus




c) Medical contraindications with respect to
the mother
Diabetes mellitus which is difficult to stabilize,
Hyperthyroidism,
Congenital heart disease; heart lesions, e. g.
fibrillation.
Owing to the danger of sudden cardiac death,
catecholamines should be used very cautiously
in cases with coronary sclerosis, hyperthy-
roidism, and severe hypertension. Concurrent
administration of calcium ions increases the
tendency to ventricular fibrillation [33].
J. Pcrinat. Mcd. 2 (1974)
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In the present article pharmacological contra-
indications are mentioned only briefly. A detailed
description is given in a separate pubücation on
the side-effects of /?-adrenergic tocolytics. Drug-
induced Inhibition o£ premature labor must be
preceded by a general medical examination, in-
cluding auscultation of the heart in particular.
There is almost complete agreement on the cli-
nical conditions required for tocolysis; however,
äs to the parameters which are considered relative
contraindications widely differing opinions have
been published. BIENARZ, CIBILS, FUCHS, and
LANDESMAN [59] regard premature rupture of the
membranes äs a contraindication because of the
danger of ascending infection. On the other hand,
KOEPCKE and SEIDENSCHNUR [32] äs well äs
WEIDINGER and WIEST [53] report on successful
Inhibition of labor following premature rupture.
Without tocolysis rupture leads to spontaneous
delivery within 3 days in 60% of all cases. In 8%
of all cases, the pregnancy is maintained until the
end of the gestation period. In the individual case
tocolysis may be tried in case of rupture. A
Prolongation of the gestation period by more
than 8 days should be achieved, this to be weighed
against the danger of infection for mother and
child. According to our own experience, we
regard rupture with considerable loss of amniotic
fluid äs a contraindication for tocolysis.
3. Indications for tocolysis
The main field of application for tocolytics is
in threatened premature labor. Premature deli-
very plays an important part in perinatal mortality
[8, 55]. Countries with a low number of premature
deliveries have better statistics concerning peri-
natal mortality, e. g. Sweden äs compared to the
USA. Before a treatment is begun, however, we
have to ask ourselves if it is advantageous to
prevent premature delivery in every case. ZSUSPAN
points to the increasing number of children with
disturbances of the central nervous System; he
finds it difficult to determine to what extent
these disturbances can be attributed to prematurity
[59].
In our opinion, prophylactic long-term medi-
cation is not indicated. "Prophylactic therapy",
in case of recurrent premature labor, must be
restricted to clinical observation or to regulär
supervision in the outpatient clinic. Additional
measures must be taken to-solve the problem of
premature delivery:
1. Family planning,
2. Adequate prenatal care,
3. Better social condition of the pregnant wo man
4. Inhibition of premature labor äs early äs
possible using specific drugs.
On the other hand we approve of prophylactic
use of tocolytics in the short-term medication,
e. g. after surgical treatment of the uterus in
pregnancy. In addition, short-term tocolysis will
generally be given to bridge the time until
delivery in cases of fetal distress. In case of ad-
ministration of ß-adrenergic substances for several
hours after surgical operations, the development
of intestinal atony must be considered. Therefore
we use post-operative tocolysis according to the
contraction pattern registered by a monitor.
The indications for tocolysis listed below will
subsequently be briefly cpmmented:
A. Premature labor with excessive uterine
activity
We do not start tocolysis bef ore the 28th week
of gestation because the ß-stimulators have
only a weak effect in early pregnancy. JUNG
et al. [29] obtained favourable results in the
treatment of imminent abortion with a drip
infusion during the 2nd to 4th month of
pregnancy.
B. Regulation of labor sub partu
a) In cases with hyperactivity and hyperkinesis
(e. g. precipitate labor in case of transverse
lie, imminent uterine rupture)
b) In some forms of hypertensive dystocia and
uncoordinated uterine contraction (in-
creased basal tone, uterine tetanus)
c) As an antidote in uterine hyperStimulation
due to oxytocin or prostaglandin (oxytocin
sensivity test, induction of labor).
With strong frequent contractions only incom-
plete transitory Inhibition canbe obtained [38].
Complete Inhibition cannot be achieyed with
,J. Perinat. Med. 2 (1074)
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/S-S}7mpathomimetics. We have been able to
observe, (äs have KOEPCKE and SEIDENSCHNUR
[32]), that after discontinuance of the tocolytic
therapy an extremely rapid dilation of the cervix
may occur.
C. Surgical treatment during pregnancy
on the uterus:




Intrafetal transfusion in erythroblastosis.
Other operations :
e. g. appendectomy
surgical treatment of biliary or renal stones.
D. Obstetric emergency cases
Complications involving the umbilical cord,
Versions and extractions,
Manual removal of the placenta.
E. Mild to medium hemorrhage due to
placenta praevia up to the 37th week of
gestation
The decision whether to apply conservative
methods in case of placenta praevia bleeding
depends on the individual clinical Situation.
Even with severe bleeding the uterus may be
sedated to prevent further Separation of the
placenta until delivery or caesarean section.
F. Intrauterine asphyxia in the course of
labor (so-called "intrauterine reanimation"
until delivery)
As a Symptom for fetal hypoxia, marked
deceleration of the chikTs heart-rate may
occur during delivery. CALDEYRO-BARCIA et al.
[15] äs well äs MOSLER [40] demonstrated
successful intrauterine treatment of the fetus
in fetal distress by means of administration of
orciprenaline or fenoterol (Th 1165 a), re-
spectively, to the mother. In the meantime
appropriate measures for completion of par-
turition may be taken. In some cases delivery
can be spontaneous. The blood gas analysis
showed an increase of the pH-value under
tocolysis [15]J
G. Gestosis (reduction in blood-pressure, simul-
taneous Stimulation of the utero-placental
blood-flow, additional infusion of a plasma
expander).
VAHRSON and SCHWARZ [49] assume an
increased utero-placental blood flow, in view
of the marked reduction of blood pressure in
the mother without danger for the child.
ZAPIOLA [57] reported on angiographical
studies in pregnant women with increased
risk: ^-Stimulation increases human utero-
placental circulation. This therapy, designed to
improve the placental ischemia, is proble-
matical in cases already demonstrating alter-
ations of the placenta.
4. Management of threatened premature
labor
We have adopted the following scheme in our
clinical management of threatened premature
labor
A. Bedrest and mild sedation:
For cases in which continuous uterine
monitoring has demonstrated only irregulär
premature uterine contractions (prematurity
in past medical history).
B. Combined tocolytic-spasmolytic ad-
ministration:
For cases in which continuous uterine moni-
toring has demonstrated regulär uterine
contractions (prematurity in past medical
history).
Immediate treatment — intravenous
Th 1165 a l—3 //g/min
Verapamil 120^g/min
(administered in 500 ml 5% Glucose).
Long^-term treatment — oral
Th 1165 a 3 mg every 4—6 hours
Verapamil 40 mg every 4—6 hours.
If there is no sufficient Inhibition of labor,
Aspirin® is given in addition
l g every 6 hours for 2—6 days orally or
rectally.
Keywords: Alcohol, Aspirin®, 0-adrenergics, halothane, premature labor, tocolysis, uterus.
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Zusammenfassung
Tokolytische Therapie in der Geburtshilfe
Unter Tokolyse versteht man die medikamentöse Hem-
mung vorzeitiger oder überschießender Uterusaktivität.
Progesteron oder inzwischen neuentwickelte Gestagen-
Präparate können die Uterusaktivität des Menschen nicht
überzeugend hemmen. Progesteron-Konzentrationen, die
in der Schwangerschaft vorkommen, können sogar sy-
nergistisch zum Oxytocin wirken und die Uterusaktivität
steigern. Nur die im Experiment anwendbaren hohen
Konzentrationen zeigen den von CSAPO inaugurierten
Block. Bewiesen wurde, daß Progesteron zusammen mit
Östrogen die StofFwechselaktivität des Uterus erhöht, es
steigert den Kollagen- sowie den Nucleinsäure-, Glykogen-
und Lipidgehalt. Therapeutisch angewendet kann es
wegen seiner geringen Wasserlöslichkeit, der hohen Af-
finität zum Serumprotein und der kurzen Halbwertzeit
auch in höchstmöglichen Konzentrationen keinen aus-
reichenden Effekt erzielen.
1. \ 'Pharmakologie der Tokolyse
Die ß-adrenergen Substanzen (Fig. 1), kontinuierlich in
kleinen Konzentrationen zugeführt, haben einen guten
tokolytischen Effekt. Über erste klinische Erfahrungen
berichteten HENDRICKS und Mitarb. sowie BISHOP und
Mitarb. Nylidrin (Buphenin, Dilatol®) fand bei uns Ein-
gang in die Therapie vorzeitiger Wehen. Ridotrin® und
Partusisten® zeigten von den später untersuchten Sub-
stanzen die beste Wirkung bei geringer Nebenwirkung.
/8-Blocker heben die Wirkung der /?-Stimulatoren auf.
Spasmolytika vorn Papaverintyp (Fig. 2) können ähn-
lich wie /?-Blocker die Herzwirkung der /?-Stimula-
toren reduzieren, gleichzeitig aber am Uterus syner-
gistisch zürn j8-Stimulator wirken. Verapamil (Isoptin®)
hat einen spasmolytischen, muskulotropen Effekt und
schien für eine Kombination mit ß-Stimulatoren geeignet.
Verapamil hat eine 5mal stärkere uterushemmende Wir-
kung als Papaverin, kann aber bei geringer Nebenwirkung
höher dosiert werden.
Die nichtsteroiden, entzündungshemmenden Stoffe
(Fig. 3) können bei längerer Einwirkung die Uterusakti-
vität hemmen, sie gelten als Prostaglandinantagonisten
(Fig. 4—6). Prostaglandine der Fraktion E2 und F2a gelten
als Mediatoren der Uterusaktivität. Die Hemmung ihrer
Synthese könnte als kausale Therapie bezeichnet werden,
wenn man voraussetzt, daß natürliche Prostaglandine zur
vorzeitigen oder überschießenden Uterusaktivität führen.
In einigen Fällen konnte im klinischen Einsatz Acetyl-
salicylsäure in Form von Colfarit® oral oder als Aspirin®-
Supp. gegeben werden (Fig. 7—8). Die Dosis betrug bis
maximal 6 g täglich. Wegen der zu erwartenden Neben-
wirkungen des Aspirins®, z. B. auf das Gerinnungssystem
und einer möglichen Kumulation, wurde die Therapie frak-
tioniert, d. h. nach 6 Tagen unterbrochen, und bei erneutem
Einsetzen von Wehen wieder begonnen.
Äthylalkohol kann in Konzentrationen von 1,0—1,6°/00
die Uterusaktivität reduzieren.
Magnesiumsulfat führt zu einer Verminderung der Wehen-
frequenz und -Amplitude. Die erforderliche Blutspiegel-
konzentration liegt jedoch mit 8—12 mg% sehr nahe an
der toxischen Grenze.
Äther zeigt am Uterus eine hervorragende relaxierende
Wirkung, kann aber wegen des postnarkotischen Er-
brechens mit Aspirationsgefahr nicht generell empfohlen
werden.
Die anästhesiologischen Eigenschaften von Halöthan
sind für die Geburtshilfe günstig, da es zu einer schnellen
Tokolyse führt. Als Nachteile gelten Herzirregularitäten
und Atemdepressionen mit Übergang in den fetalen Kreis-
lauf und der Gefahr der Atemdepression.
2. Klinik der Tokolyse
Die modernen Tokolytika sind hochwirksame Pharmaka,
deshalb sollte die Tokolyse Kliniken mit ärztlicher Ge-
burtshilfe vorbehalten bleiben. Eine apparative und per-
sonelle Pauerüberwachung während der Behandlung
sollte möglich sein. Für die externe Dauerüberwachung
eignen sich der Phoriokardiotokograph und der Ültra-
schallkardiotokograph.
Die größte Hoffnung auf eine Verringerung der perinatalen
Mortalität könnte durch die Senkung der Frühgeburten-
zahl erzielt werden. Für eine erfolgreiche Tokolyse sind
einige Voraussetzungen erforderlich:
1. Koordinierte Wehentätigkeit mit einer Frequenz von
l und mehr Wehen in 10 Minuten.
2. Lebender Fet.
3. Geschätztes Gewicht des Feten unter 2.500 g bzw.
Tragzeit bis zur 37. Woche.
4. Muttermund bis maximal 3 cm eröffnet.
5. Zervix weniger als die Hälfte verkürzt.
Als relative klinische Kontraindikation gelten: der vor-
zeitige Blasensprung, Temperaturen über 38°C bei Ver-
dacht auf intrauterine Infektion, starke Blutungen bei
Placenta praevia, vorzeitige Plazentalösung sowie Miß-
verhältnis, z. B. bei engem Becken.
Als relative medizinische Kontraindikation von seiten
des Feten gelten: pathologische Herzfrequenzrnuster ohne
Wehen, nachgewiesene Mißbildung, Erythroblastose und
Hydramnion mit Verdacht auf Mißbildung.
Als relative medizinische Kontraindikation von seiten
der Mutter haben zu gelten: ein manifester schwer ein-
stellbarer Diabetes mellitus, angeborene Herzkrankheiten,
kardiale Arrhythmien, Hyperthyreose und schwere Hyper-
tonie. Gleichzeitige Gabe von Kalziumionen verstärkt die
Tendenz zum Kammerflimmern.
3. Indikation zur Tokolyse
1. Vorzeitige Wehentätigkeit mit drohender Frühgeburt.
2. Wehenregulierung bei Hyperaktivität des Uterus,
Tetanus uteri,
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Antidot bei Überstimulierung mit Oxytocin oder
Prostaglandinen.
3. Operationen in graviditate
Cerclage
Myomenucleation






Involutio uteri post partum, Reposition
5. Schwache bis mittelstarke Placenta-praevia-Blutung
bis zur 37. Gestationswoche.
6. Intrauterine Asphyxie in der Austreibungsperiode.
7. Gestose.
4. Behandlung der drohenden Frühgehurt
Nach folgenden Richtlinien kann die klinische Behandlung
der drohenden Frühgeburt durchgeführt werden:
a) Bettruhe und leichte Sedierung in Fällen von unregel-
mäßiger vorzeitiger Uterusaktivität.
b) Kombinierte tokolytische und spasmolytische Therapie
in Fällen, in welchen die kontinuierliche Uterusaktivität
in stärker werdende, reguläre Uterusaktivität übergeht.
Die akute Behandlung beginnt intravenös mit ß-Sü-
mulatoren, z. B. Th 1165a l—3yug/min, zur Vermeidung
von Nebenwirkungen Verapamil 120//g/min in 5%iger
Glucoselösung.
Langzeitbehandlung oral Th 1165 a 3—5 mg alle A—6
Stunden, Verapamil zusätzlich 40—80 mg alle 4—8 Stun-
den.
Setzt keine ausreichende Hemmung der Wehentätigkeit ein,
dann kann der Versuch unternommen werden, Aspirin l g
alle 6 Stunden für 2 maximal 6 Tage oral oder rectal zu-
zuführen.
Schlüsselwörter: Äthylalkohol, Aspirin, /?-Adrenergika, Halothan, Wehen (vorzeitig), Tokolyse.
Resume
Therapie tocolytique en obstetrique
Par tocolyse on entend l'inhibition medicamenteuse de
Pactivite uterine prematuree ou excessive. Le progesterone
ou les preparations de gestagenes mises au point entre-
temps ne peuvent pas inhiber de fagon convaincante
Pactivite uterine humaine. Les concentrations de pro-
gesterone qui se produisent dans la grossesse peuvent
meme avoir un effet synergetique d'oxytocine et accroitre
Pactivite uterine. Seulemente les concentrations elevees
applicables en experimentation montrent le bloc inaugure
par CS A PO. II a ete prouve que le progesterone avec
Poestrogene augmente Pactivite metabolique de Puterus
ainsi que la teneur en collagenes de meme qu'en acide
nucleique, glyogene et lipides. Applique de facon thera-
peutique, il ne peut pas atteindre un effet süffisant meme
sous forme de concentrations maximales en raison de son
hydrosolubilite reduite, de sä grande affinite avec la
plasmaproteine, et de sä courte periode de demi-valeur.
1. Pharmacologie de la tocolyse
Les substances ß-adrenergiques (Fig. 1), administrees de
fagon continue en concentrations faibles ont, un bon effet
tocolytique. HENDRICKS et coll. ainsi que BISHOP et coll.
ont parles des premieres experiences cliniques. La nylidrine
(buphenine, dilatol®) etait employee chez nous en therapie
pour les douleurs prematurees. Parmi les substances exa-
minees par la suite, la ridotrine® et les partpsistes® se
montrerent les plus efficaces avec un effet secondaire
reduit.
Les agents bloqueurs stoppent Peffet des stimulateurs.
Des substances spasmoly-figiires (Fig. 2) du type de
papaverine peuvent, de fagon similalre aux blockeurs,
reduire l'eifet cardiaque des stimulateurs, mais agir
en meme temps de fa$on synergetique sur Puterus
comme un stimulateur. Le verapamil (isoptin®) a un
effet spasmolytique, musculotrope et a semble convenir a
une combinaison avec les stimulateurs. Le verapamil a un
effet inhibiteur sur l'uterus 5 fois superieur a celui de la
papaverine et, en cas d'effet secondaire reduit, son dosage
peut etre encore augmente.
Les agents nonsteroides, inhibitrices des inxamma-
tions (Fig. 3), peuvent, sous action prolongee, inhiber
Pactivite de Puterus et ont valeur des antagomstes des
prostaglandines (Fig. 4—6). Les prostaglandines de la
fraction E2 etF2ocsont considerees comme des mediateurs
de Pactivite uterine. L'inhibition de leur Synthese pourrait
etre qualifiee de therapie causale si on part du fait que les
prostaglandines naturelles conduisent a une activite uterine
prematuree ou excessive. Dans quelques cas, on a pu, en
Intervention clinique, administrer de Pacide acetyle
salicylique sous forme de colfarit® par voie buccale ou de
suppositoires d'aspirine® (Fig. 7—8). La dose maximale a
ete de 6 g par jour. A cause des effets secondaires probables
de Paspirine, sur le Systeme de coagulation par exemple, et
d'une cumulation eventuelle, la therapie a ete fractionnee,
c. a. d. interrompue apr£s 6 jours pour etre recommencee a
la reprise des douleurs.
L'alcool ethylique, concentre a 1,0—1,6°/00, peut reduire
Pactivite uterine.
Le sulfate de magnesium provoque une diminution de la
frequence et de Pamplitude des douleurs. Mais la concen-
tration du taux sanguin requise etant de 8—12 mg%, eile
se trouve tres pres de la limite toxique.
L'ether manifeste dans Puterus une excellente action
relaxante, mais ne peut malgre tout pas etre recommande
d'une fagon g£nerale cause des vomissements postnar-
cotiques avec risque d'aspiration.
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Les propriotos anesthesiologiques de Fhalothan sont
favorables en obstetrique, car il provoque une tocolyse
rapide. Les inconvonients en sont, toutefois, les irrd-
gularites cardiaques et depressions respiratoires avec
passage dans la circulation foetale et danger de depression
respiratoire chez le nouveau-ne.
2. Aspects cliniques de la tocolyse
Les tocolytica modernes sont des medicaments tres ef-
ficaces; la tocolyse devrait donc etre reservee aux höpitaux
dotes d'un Service medical d'obstetrique, avec surveillance
assuree en permanence pendant le traitment par im
personnel et des appateils süffisante. Le phonocardio-
tocographe et l'ultrasonocardiotocographe sont recomman-
des pour la surveillance permanente externe.
On peut esperer reduire la mortalite perinatale en premier
lieu en abaissant le nombre des accouchements prematures.
Une tocolyse reussie presuppose:
1. un travail d'accouchement coordonne avec une fre-
quence de l ä plusieurs douleurs par dix minutes;
2. un foetus vivant;
3.'un poids du foetus estime inferieur a 2500 g ou une
duree de grossesse n'ayant pas depasse 37 semaines;
4. une ouverture de Forifice de Futerus ne depassant
pas 3 cm;
5. un col de Futerus raccourci de moins de la moitie.
Les facteurs de contre-indication clinique relative
sont: la rupture prematuree des membranes, des tempera-
tures superieures a 38°C avec suspicion d'infection intra^·
uterine, des fortes hemorragies par placenta praeviä, le
detachement premature du placenta ainsi qu'une dispro-
portion, par ex. en cas d'etroitesse du bassin.
Les facteurs de contre-indication medicale relative
chez le foetus sont: Fechantillon de frequence cardiaque
pathologique en l'absence des douleurs du travail, une
malformation prouvee, une erythroblastose et une poly-
hydramnie avec suspicion de malformation.
Les facteurs de contre-indication medicale relative
chez la mere sont: un diabetes mellitus manifeste et
difficilement contrölable, des maladies cardiaques con-
genitales, des arrhytmies cardiales, Phyperthyreose et une
Hypertonie grave. Une administration simultanee de
calciumions accroit la tendance de vibrations ventriculaires.
3. Indications pour la tocolyse
1. Travail promarur£ avec risque d'accouchement pre-
mature. : l
2. R£gulation du travail en cas d'hyperactivite de F
uterus, tetanus uteri,
antidote en cas de Stimulation excessive par oxytocine
ou prostaglandines.
3. Operation pendant la gravidite,
cerclage,
myomenucleation,






involutio uteri post partum.
5. Hemorragie placentaire de faible ä mesosthenique
jusqu'a la 37£me semaine de gestation.
6. Asphyxie intra-uterine dans la periode d'expulsion.
7. Gestose.
4. Le traitement clinique de Faccouchement pre-
mature
Le traitement clinique de l'accouchement premature
menagant peut etre applique en accord avec les directives
suivantes:
a) Repos au lit et sedation legere dans les cas d'activite
uterine prematuree et irreguliere.
b) Therapie tocolytique et spasmolytique combinee dans
les cas ou Factivite uterine continue devient reguliere
et plus forte.
Le traitement intensif commence par voie intraveineuse
avec des stimulateurs, par ex. Th 1165 a l—3//g/min,
pour prevenir les effets secondaires veräpamil 120/^g/min
dans du glucose 5%.
Traitement de longue duree par voie buccale Th 1165a
3—5 mg toütes les A—-6 heures, avec, en plus, veräpamil
40—80 mg toütes les 4—8 heures.
Si ces traitements ne suffisent pas a inhiber le travail, on
peut essayer d'administrer l g d'aspirine toütes les 6 heures
pendant 2 maximum 6 jours par voie buccale oü rectale.
Mots-cles: tocolyse, travail premature et son traitment, Inhibition du travail, sedatifs uterins, substances stimulateurs
sur Futerus humain, effet de Faspirine sur Futerus humain.
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